Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
Clinical trial NCT03478787 · COMPLETED
Trial details
- NCT number
- NCT03478787
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-08
- Primary completion
- 2020-07-08
- Enrollment
- 327
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.